Formulation Development
AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial
AC Immune SA recently announced it has received a milestone payment from its partner Life Molecular Imaging in connection with the initiation of….
DURECT Earns $10-Million Milestone Payment From Gilead
DURECT Corporation recently announced that further development of a long-acting injectable HIV investigational product utilizing DURECT’s SABER technology has triggered a $10-million milestone payment from Gilead Sciences, Inc. to…….
Pfenex Earns $11-Million Development Milestone
Pfenex Inc. recently announced it has earned an $11-million development milestone under its development and license agreement with Jazz Pharmaceuticals. The milestone is associated with…….
FUJIFILM Irvine Scientific Launches BalanCD Gal Supplement for Biotherapeutic Development
The new formula has been developed to increase galactosylation in biotherapeutic development, to help achieve….
Kaleido Biosciences to Collaborate with Gustave Roussy Cancer Center
Kaleido Biosciences, Inc. recently announced plans to develop Microbiome Metabolic Therapies (MMT) to enhance the effects of cancer immunotherapies under a new…….
Fate Therapeutics Announces FDA Clearance of IND Application
Fate Therapeutics, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for FT596, the company’s first off-the-shelf chimeric antigen…
Krystal Biotech Announces Initiation of Phase 1/2 Study
Krystal Biotech Inc. recently announced the initiation of the Phase 1/2 study of KB105 in transglutaminase-1 (TGM1) deficient autosomal recessive congenital ichthyosis (ARCI). The study, termed…
Atossa Genetics Announces Completion of Enrollment & Dosing in Phase 1 Clinical Trial
Atossa Genetics Inc. recently announced that all participant activities have been completed in its Phase 1 clinical trial of a new proprietary modified-release oral tablet form…
Innovent & Lilly Set to Transform Diabetes Medication as Clinical Trials Begin
Innovent Biologics, Inc. recently signed a licensing agreement with Eli Lilly and Company (Lilly), one of America’s leading pharmaceutical companies, for the development and potential…
Apellis Dosed First Patient in Phase 3 Study
Apellis Pharmaceuticals Inc.recently announced the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2…
Passage Bio Closes $110-Million Series B Financing
Passage Bio recently announced the closing of a $110-million Series B financing. The financing round was led by Access Biotechnology with participation from existing investors,…
Nkarta Therapeutics Raises $114 Million in Series B Financing to Advance Multiple Programs Into Clinical Trials
This financing is intended to support two clinical trial programs of NKX101, Nkarta’s allogenic NK cell therapy targeting NKG2D, in patients with either…..
Foamix Announces New US Patent That Expires in 2037
Foamix Pharmaceuticals Ltd. recently announced the US Patent and Trademark Office has issued US Patent No. 10,398,641 covering a method of treating…….
Kintai Therapeutics Announces Collaborations With Leading Academic Centers
Kintai Therapeutics recently announced it has established new collaborations with leading academic institutions to identify novel molecules that play a fundamental role in microbe to…
PCI Strengthens Position in Europe With Investment in Ireland
PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has solidified its leadership position in the EU with strategic investment to deepen its presence…
Adaptimmune & Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products
Adaptimmune Therapeutics plc and Noile-Immune Biotech, Inc. recently announced they will co-develop next-generation SPEAR T-cell products, incorporating Noile-Immune’s PRIME (proliferation inducing and migration enhancing) technology,…
Hovione Signs Collaboration Agreement With Kiel University on High-Dose Dry Powder Inhalation Delivery
Hovione Technology recently announced it has entered into a collaboration agreement with Kiel University, Institute of Pharmacy in Germany, a reference research institution on inhaled drug delivery.